NRC Health reported first‑quarter 2026 revenue of $34.8 million, a 4% year‑over‑year increase, and adjusted earnings per share of $0.21, up from $0.16 in the fourth quarter of 2025. The company’s GAAP net income fell to $3.2 million from $5.8 million in Q1 2025, while diluted EPS declined to $0.14 from $0.25 year‑over‑year, underscoring the impact of higher operating expenses and the shift to adjusted metrics.
Total recurring contract value (TRCV) reached a record $152.1 million, up 13% from the prior year and the largest deal signed in the company’s 45‑year history. CEO Trent Green said, "We delivered a strong start to 2026, with record Total Recurring Contract Value and our first quarter of year‑over‑year revenue growth since 2023, reflecting the tangible momentum building across our business." The growth was driven by robust demand for the Human Understanding platform and a multi‑year high in customer retention, as Green noted, "Our new sales and customer retention both reached multi‑year highs this quarter, underscoring the trust our customers place in us."
Adjusted EBITDA margin held steady at 27.0%, a sequential improvement from Q4 2025, while operating cash flow rose 8% year‑over‑year to $7.2 million. CFO Shane Harrison explained, "Q1 adjusted EBITDA was $9.4 million, representing a 27% margin," and added that free cash flow was up nearly 50% year‑over‑year to $5.3 million. Harrison also warned that implementation costs for the landmark deal would keep margins flat in Q2, with expansion expected in Q3 as revenue aligns with the recent TRCV trend.
Management projected continued momentum, noting that the company’s guidance for the remainder of 2026 remains positive. Harrison said, "We expect these rollout costs will keep our adjusted EBITDA margin flattish sequentially in Q2 with margins beginning to expand in Q3 and beyond as overall revenue begins to more fully reflect our recent TRCV trend." The company plans Phase 1 of the new platform to go live in Q3 2026, representing roughly half of the expected annualized revenue, with Phase 2 slated for Q3 2027.
Market reaction was tempered by valuation concerns and near‑term margin pressures. The stock slipped 1.23% in aftermarket trading, closing at $16.90, as investors weighed the company’s premium valuation and the anticipated impact of implementation costs. Green added that the pending Qualtrics‑Press Ganey transaction may have slowed some buying processes.
Additional context: NRC Health declared a quarterly dividend of $0.16 per share, payable July 10 2026, and announced a $60 million share repurchase authorization in March 2026. The company also expects a $9.4 million charge in Q2 2026 related to equity award modifications, which will not affect adjusted EBITDA.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.